Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Anita Boyapati"'
Autor:
Kusha Mohammadi, Mark W. Sleeman, Anita Boyapati, Parnian Bigdelou, Gregory P. Geba, Sergio Fazio
Publikováno v:
Journal of Lipid Research, Vol 65, Iss 6, Pp 100568- (2024)
Plasma lipid levels are modulated by systemic infection and inflammation; it is unknown whether these changes reflect inflammatory responses or caused directly by pathogen presence. We explored the hypothesis that anti-inflammatory intervention via i
Externí odkaz:
https://doaj.org/article/633c86a104e5483a93ce1b94434bc2f3
Autor:
Hans C. Lee, Naresh Bumma, Joshua Richter, Madhav Dhodapkar, James E. Hoffman, Attaya Suvannasankha, Jeffrey Zonder, Mansi R. Shah, Suzanne Lentzsch, Joseph J. Maly, Jing Christine Ye, Ka Lung Wu, Michelle Deveaux, Dhruti Chokshi, Anita Boyapati, Anasuya Hazra, Karen Rodriguez Lorenc, Glenn Kroog, Yariv Houvras, Sundar Jagannath
Publikováno v:
HemaSphere, Vol 7, p e1610068 (2023)
Externí odkaz:
https://doaj.org/article/ebffe14a73ae40d0a1f44b84269e2dd0
Autor:
Katja Weisel, Vania Hungria, Hang Quach, Sung-Soo Yoon, Paula Rodríguez-Otero, Glenn Kroog, Arijit Sinha, Anita Boyapati, Charlotte Lyon, Karen Rodriguez Lorenc, Timothy Inocencio, James Harnett, Lei Chi, Vygngley Moore, Peter Voorhees
Publikováno v:
HemaSphere, Vol 7, p e465366a (2023)
Externí odkaz:
https://doaj.org/article/331bd93f48144d34a96f1aff164681fb
Autor:
Christopher J. Ferreri, Steven Quatela, Oluwaseun Aina, Pourab Roy, Anita Boyapati, Karen Rodriguez Lorenc, Glenn Kroog, Robert Z Orlowski
Publikováno v:
HemaSphere, Vol 7, p e5212351 (2023)
Externí odkaz:
https://doaj.org/article/5490ccc23ee44d33a04f2f40ee7fa039
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-9 (2020)
Abstract Background Increased levels of cytokines, including interleukin-6 (IL-6), reflect inflammation and have been shown to be predictive of therapeutic responses, fatigue, pain, and depression in patients with rheumatoid arthritis (RA), but limit
Externí odkaz:
https://doaj.org/article/b860e9616b7c45618cb4e77fed50f962
Autor:
Pavel Kovalenko, Anne Paccaly, Anita Boyapati, Christine Xu, Gregory St John, Michael C. Nivens, John D. Davis, Ronda Rippley, A. Thomas DiCioccio
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 7, Pp 405-414 (2020)
Evidence suggests that effects of interleukin‐6 pathway inhibitors sarilumab, tocilizumab, and sirukumab on absolute neutrophil count (ANC) are due to margination of circulating neutrophils into rapidly mobilizable noncirculating pools. We develope
Externí odkaz:
https://doaj.org/article/67c9b10110704a98b5052e51a5d05f23
Autor:
Cem Gabay, Gerd R. Burmester, Vibeke Strand, Jérôme Msihid, Moshe Zilberstein, Toshio Kimura, Hubert van Hoogstraten, Susan H. Boklage, Jonathan Sadeh, Neil M. H. Graham, Anita Boyapati
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020)
Abstract Background Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a key role in the pathogenesis of rheumatoid arthritis. Sarilumab is a human monoclonal antibody that binds membrane-bound and soluble IL-6 receptor-α to inhibit IL-6 sign
Externí odkaz:
https://doaj.org/article/9f7d47705237485b86eba702a5fcce61
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/7e0578f828b44b3bb5062556a5e5ff96
Supplementary Data from 3-Phosphoinositide–Dependent Protein Kinase-1 Regulates Proliferation and Survival of Cancer Cells with an Activated Mitogen-Activated Protein Kinase Pathway
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::144b149a15569bb22e5cfb1913e41a0e
https://doi.org/10.1158/1541-7786.22519194.v1
https://doi.org/10.1158/1541-7786.22519194.v1
Autor:
Nan Lin, Amy Damask, Anita Boyapati, Jennifer D. Hamilton, Sara Hamon, Nils Ternes, Michael C. Nivens, John Penn, Alexander Lopez, Jeffrey G. Reid, John Overton, Alan R. Shuldiner, Goncalo Abecasis, Aris Baras, Charles Paulding
Publikováno v:
The Pharmacogenomics Journal. 22:160-165
Sarilumab is a human monoclonal antibody against interleukin (IL)-6Rα that has been approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) and an inadequate response or intolerance to one or more di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d61fa204c8862547a651af46bed3c9fb
https://doi.org/10.1038/s41397-022-00269-5
https://doi.org/10.1038/s41397-022-00269-5